Author

V.S.S. Abhinav Ayyadevara

Loma Linda UniversityORCID 0000-0003-2085-2588Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

Christian HurtziD· 2 shared Ashley Paik· 1 shared Ashlyn ConantiD· 1 shared Ethan Nyein· 1 shared Gary YuiD· 1 shared Gerald B. W. WertheimiD· 1 shared Huimin GengiD· 1 shared Jacqueline S. Coats· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Christian HurtzORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyMolecular OncologyPeer-reviewedJul 10, 2026

Interferon Beta Drives Therapy Resistance in a Patient Derived Model of High Grade Serous Ovarian Cancer

Ashlyn Conant, Tise Suzuki, Kiera McGivney…·Juli Unternaehrer

This study shows that IFN-beta drives therapy resistance in HGSOC models through cell-autonomous signaling, independent of DNA damage.

2 citationstop 1%

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologybioRxivPreprintJul 8, 2025

Selective Sensitivity of Ph-like B-ALL to BRG1 Inhibition Reveals a Novel Targeted Therapy Strategy

V.S.S. Abhinav Ayyadevara, Shikha Gaur, Ashley Paik…·Christian Hurtz

This study identifies BRG1 as a critical target in Ph-like B-ALL, showing its inhibition leads to cell cycle arrest and improved survival in preclinical models.

DOI 10.1101/2025.07.08.661805

humanbulk RNA-seq

𝕏 PostBluesky